** Shares of drugmaker Gilead GILD.O rise 2% to $82.55
** Co says its HIV injectable drug lenacapavir reduced HIV infections by 96% and was superior to daily pill Truvada in second late-stage trial
** The study included cisgender men, transgender men, transgender women, and gender -binary individuals who have sex with partners assigned male at birth
** In June, co said a late-stage study showed the long-acting drug lenacapavir was more effective in preventing HIV infection in women vs Truvada
** Co will begin a series of global regulatory filings by the end of 2024
** Stock up ~2.8% YTD
(Reporting by Sriparna Roy in Bengaluru)